Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, MD, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141296

Published: 2020

Journal Articles

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Clemence Marcault, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-136177

Published: 2020

Journal Articles

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

Rafael Daltro De Oliveira, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Clemence Marcault, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Nathalie Parquet, MD, Emmanuel Raffoux, MD, William Vainchenker, Christine Chomienne, MD PhD, Bruno Cassinat, PharmD, PhD, Lina Benajiba, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141223

Published: 2020

Journal Articles

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Pierre-Edouard Debureaux, Bruno Cassinat, PharmD, PhD, Juliette Soret-Dulphy, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Pierre-Emmanuel Rautou, MD PhD, Aurelie Plessier, Dominique Valla, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 836.

https://doi.org/10.1182/blood-2019-123775

Published: 2019

Journal Articles

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Bridget Marcellino, MD PhD, Bruno Cassinat, PharmD, PhD, Noushin Farnoud, PhD, Min Lu, PhD, Emmanuelle Verger, PhD, Erin McGovern, BA, Minal A Patel, MPH, Heidi E. Kosiorek, MS, Meenakshi Mehrotra, PhD, Jane Houldsworth, PhD, Amylou C. Dueck, PhD, Michael Rossi, PhD, Jean-Jacques Kiladjian, MD PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 838.

https://doi.org/10.1182/blood-2019-128342

Published: 2019

Journal Articles

Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic

Nabih Maslah1, PharmD, Tracy Dagher, PhDstudent, Valérie Edmond, PhD, Bruno Cassinat, PharmD, PhD, Valérie Lallemand-Breitenbach, PhD, Emmanuelle Verger, PhD, Isabelle Plo, PhD, Jean-Jacques Kiladjian, MD PhD, Jean-Luc Villeval, PhD, Hugues de Thé, MD PhD

Blood (2018) 132 (Supplement 1): 52.

https://doi.org/10.1182/blood-2018-99-112518

Published: 2018

Journal Articles

JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics

Anna Guadall, PhD, Elodie Lesteven, PharmD, PhD, Gil Letort, Sarah Awan Toor, Doriane Pognant, Megane Brusson, Emmanuelle Verger, PhD, Jerome Larghero, PharmD, PhD, Valerie Vanneaux, PharmD, PhD, Christine Chomienne, MD PhD, Wassim El Nemer, PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 4273.

https://doi.org/10.1182/blood.V128.22.4273.4273

Published: 2016

Journal Articles

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Juliette Soret, MD, Bruno Cassinat, PharmD, PhD, Sylvie Chevret, MD PhD, Christine Dosquet, MD PhD, Stephane Giraudier, MD PhD, Emmanuelle Verger, PhD, Nabih Maslah, PhD, Nathalie Parquet, MD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 3106.

https://doi.org/10.1182/blood.V128.22.3106.3106

Published: 2016

Journal Articles

Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET)

Emmanuelle Verger, PhD, Bruno Cassinat, PharmD, PhD, Christine Dosquet, MD PhD, Marie-Helene Schlageter, Valérie Ugo, MD PhD, Jean-Christophe Ianotto, MD, Mohamed A. Yassin, MBBS ,MSc,CABM,FACP, Nader Dewik, PhD, Serge Carillo, PhD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 407.

https://doi.org/10.1182/blood.V124.21.407.407

Published: 2014

Journal Articles

Impact of the JAK2V617F Mutation on the Hemato-Endothelial Differentiation in an Induced Pluripotent Stem Cells (iPSC) Model

Elodie Lesteven, PharmD, PhD, Doriane Pognant, Valerie Vanneaux, PharmD, PhD, Jérome Larghero, PharmD, PhD, Olivier Feraud, Annelise Bennaceur-Griscelli, MD PhD, Emmanuelle Verger, PhD, Annalisa Andreoli, MD, Christine Chomienne, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 4570.

https://doi.org/10.1182/blood.V124.21.4570.4570

Published: 2014

Journal Articles

AOP2014/P1101, a Novel Peg-Proline-Interferon Alpha (IFNa) 2b, Specifically Targets JAK2V617F-Positive Polycythemia Vera (PV) Cells

Emmanuelle Verger, PhD, Bruno Cassinat, PharmD, PhD, Annalisa Andreoli, MD, Elodie Lesteven, PharmD, MSc, Christoph Klade, PhD, Oleh Zahriychuk, MD, MSc, Christine Chomienne, MD, PhD, Jean-Jacques Kiladjian, MD, PhD

Blood (2013) 122 (21): 1611.

https://doi.org/10.1182/blood.V122.21.1611.1611

Published: 2013

Journal Articles

Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain

Annalisa Andreoli, MD, Emmanuelle Verger, PhD, Marie Robin, MD, PhD, Emmanuel Raffoux, Jean-Marc Zini, MD, PhD, Philippe Rousselot, MD, PhD, Gérard Socié, MD, PhD, Delphine Rea, MD, PhD, Nathalie Parquet, MD, Stephane Giraudier, MD, PhD, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD, PhD

Blood (2013) 122 (21): 1591.

https://doi.org/10.1182/blood.V122.21.1591.1591

Published: 2013

NARROW

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic

JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET)

Impact of the JAK2V617F Mutation on the Hemato-Endothelial Differentiation in an Induced Pluripotent Stem Cells (iPSC) Model

AOP2014/P1101, a Novel Peg-Proline-Interferon Alpha (IFNa) 2b, Specifically Targets JAK2V617F-Positive Polycythemia Vera (PV) Cells

Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only